Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Last trade$206.56
Day change-$8.71 (-4.05%)
Day range$203.98 – $220.86
Volume5,324,410
Market cap$87.10B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$87.1B
Price / earnings
—
Price / book
12.74×
Price / sales
34.5×
EV / sales
35.43×
EV / EBITDA
-33.47×
Profitability
Earnings per share
-$6.89
Return on assets
-20.71%
Return on equity
-40.79%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.52×
Current ratio
3.62×
Quick ratio
3.47×
Cash ratio
0.59×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$1.97B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MRNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.31B
$145M
$389M
$678M
$1.02B
$142M
$108M
$966M
Cost of revenue
$318M
$93M
$955M
$452M
$207M
$119M
$90M
$739M
Gross profit
$995M
$52M
-$566M
$226M
$809M
$23M
$18M
$227M
Selling, general and administrative
$282M
$216M
$173M
$308M
$268M
$230M
$212M
$351M
Research and development
$583M
$651M
$649M
$775M
$801M
$700M
$856M
$1.12B
Total operating expenses
$865M
$867M
$822M
$1.08B
$1.07B
$930M
$1.07B
$1.47B
Operating income
$130M
-$815M
-$1.39B
-$857M
-$260M
-$907M
-$1.05B
-$1.25B
Interest expense
-$18M
-$17M
$0
$0
$0
-$1M
$0
$0
Income before taxes
$171M
-$767M
-$1.33B
-$799M
-$187M
-$818M
-$964M
-$1.18B
Income taxes
$9M
$15M
$9M
$27M
$13M
$7M
$7M
-$64M
Net income
$162M
-$782M
-$1.34B
-$826M
-$200M
-$825M
-$971M
-$1.12B
Net income attributable to common shareholders
$162M
-$782M
-$1.34B
-$826M
-$200M
-$825M
-$971M
-$1.12B
EBITDA
$198M
-$752M
-$1.33B
-$790M
-$208M
-$850M
-$1.01B
-$1.19B
Basic earnings per share
$0.40
-$1.97
-$3.40
-$2.11
-$0.51
-$2.13
-$2.52
-$2.91
Diluted earnings per share
$0.38
-$1.97
-$3.40
-$2.11
-$0.51
-$2.13
-$2.52
-$3.02
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.
Moderna outlined its growth strategy at its 2026 Analyst Day, highlighting oncology as a key long-term opportunity with intismeran autogene for melanoma treatment. However, shares fell 7% as the company projected $4 billion in 2027 cash costs and $4-$4.5 billion annually through 2030, while providing limited visibility into 2027 and longer-term revenue growth.
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.